The interdepartmental CURE: Digestive Diseases Research Core Center (CURE: DDRCC), funded continuously since 1989, is composed of 68 members and 26 associate members comprising a multidisciplinary group of physicians and basic scientists with strong independent peer-reviewed grant-supported programs in basic, translational and clinical research of the digestive system. Annual direct digestive diseases-related grant support for the research base is $16,858,584 including $6,089,729 from NIDDK. The current programs of this Research Base can be broadly divided in three major and interrelated complementary areas: A) Molecular and integrative mechanisms of gastrointestinal and pancreatic physiology and inflammation; B) Bidirectional brain-gut interactions and functional disorders of the digestive system; C) Mechanism of action of neuro-hormonal Gl signals: receptor regulation, signal transduction and control of normal and abnormal cell proliferation. The Biomedical Research Cores outlined in this proposal provide ready access to technologies and to clinical and biological materials that are essential to the programs of center members. These Cores offer access to modern cellular imaging to study signaling proteins and their functions, facilitate intestinal stem cell biology, provide animal models and techniques for studying integrative physiology and pathophysiology, molecular vectors to express a wide variety of proteins and access to a broad range of techniques and patients for clinical studies. The Administrative Core gives a wide range of administrative support for members and for center activities, including a comprehensive and multidisciplinary enrichment program. The Pilot and Feasibility Study program has provided a very successful mechanism for promoting the development of new programs and ideas in digestive diseases related research, primarily by young investigators. The CURE: DDRCC, enhanced by substantial direct institutional support, provides a forum, strategic vision and programmatic integration in which faculty members can advance the understanding of fundamental mechanisms relating to the function, disorders and diseases of the digestive system by making their combined efforts much greater than the sum of the parts.

Public Health Relevance

The CURE DRRCC comprises a multidisciplinary research base dedicated to advancing our understanding of the biology, functional disorders and diseases of the digestive system. Scientific core facilities, Pilot and Feasibility Study awards an enrichment programs provide a platform of novel technologies, services and interactions to promote the collaborative research efforts of the CURE: DDRCC membership.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Center Core Grants (P30)
Project #
5P30DK041301-27
Application #
9003042
Study Section
Special Emphasis Panel (ZDK1-GRB-8 (M2))
Program Officer
Perrin, Peter J
Project Start
1996-12-01
Project End
2019-11-30
Budget Start
2015-12-01
Budget End
2016-11-30
Support Year
27
Fiscal Year
2016
Total Cost
$842,809
Indirect Cost
$211,686
Name
University of California Los Angeles
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
092530369
City
Los Angeles
State
CA
Country
United States
Zip Code
90095
Bonfiglio, Ferdinando; Zheng, Tenghao; Garcia-Etxebarria, Koldo et al. (2018) Female-Specific Association Between Variants on Chromosome 9 and Self-Reported Diagnosis of Irritable Bowel Syndrome. Gastroenterology 155:168-179
Hoffman, Jill M; Sideri, Aristea; Ruiz, Jonathan J et al. (2018) Mesenteric Adipose-derived Stromal Cells From Crohn's Disease Patients Induce Protective Effects in Colonic Epithelial Cells and Mice With Colitis. Cell Mol Gastroenterol Hepatol 6:1-16
Kageyama, Shoichi; Nakamura, Kojiro; Fujii, Takehiro et al. (2018) Recombinant relaxin protects liver transplants from ischemia damage by hepatocyte glucocorticoid receptor: From bench-to-bedside. Hepatology 68:258-273
Wen, Yi; Scott, David R; Vagin, Olga et al. (2018) Measurement of Internal pH in Helicobacter pylori by Using Green Fluorescent Protein Fluorimetry. J Bacteriol 200:
Koon, Hon Wai; Wang, Jiani; Mussatto, Caroline C et al. (2018) Fidaxomicin and OP-1118 Inhibit Clostridium difficile Toxin A- and B-Mediated Inflammatory Responses via Inhibition of NF-?B Activity. Antimicrob Agents Chemother 62:
Wang, Jiani; Ghali, Sally; Xu, Chunlan et al. (2018) Ceragenin CSA13 Reduces Clostridium difficile Infection in Mice by Modulating the Intestinal Microbiome and Metabolites. Gastroenterology 154:1737-1750
Manatsathit, Wuttiporn; Khrucharoen, Usah; Jensen, Dennis M et al. (2018) Laparotomy and intraoperative enteroscopy for obscure gastrointestinal bleeding before and after the era of video capsule endoscopy and deep enteroscopy: A tertiary center experience. Am J Surg 215:603-609
Rankin, Carl Robert; Theodorou, Evangelos; Man Law, Ivy Ka et al. (2018) Identification of novel mRNAs and lncRNAs associated with mouse experimental colitis and human inflammatory bowel disease. Am J Physiol Gastrointest Liver Physiol 315:G722-G733
Park, S H; Naliboff, B D; Shih, W et al. (2018) Resilience is decreased in irritable bowel syndrome and associated with symptoms and cortisol response. Neurogastroenterol Motil 30:
Dong, Tien; Pisegna, Joseph (2018) Passing the ""Acid Test"": Do Proton Pump Inhibitors Affect the Composition of the Microbiome? Dig Dis Sci :

Showing the most recent 10 out of 1097 publications